GRI Bio, Inc. Common Stock
Symbol: GRI (NASDAQ)
Company Description:
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
- Today's Open: $1.96
- Today's High: $2.08
- Today's Low: $1.93
- Today's Volume: 326.75K
- Yesterday Close: $1.98
- Yesterday High: $1.995
- Yesterday Low: $1.9
- Yesterday Volume: 189.64K
- Last Min Volume: 2.00K
- Last Min High: $2.077
- Last Min Low: $2.06
- Last Min VWAP: $2.06375
- Name: GRI Bio, Inc. Common Stock
- Website: https://www.gribio.com
- Listed Date: 2023-04-24
- Location: LA JOLLA, CA
- Market Status: Active
- CIK Number: 0001824293
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $4.98M
- Round Lot: 100
- Outstanding Shares: 2.52M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-22 | 4 | View |
| 2025-09-22 | 4 | View |
| 2025-09-22 | 4 | View |
| 2025-09-22 | 4 | View |
| 2025-09-22 | 4 | View |
| 2025-09-22 | 4 | View |
| 2025-09-22 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 4 | View |
| 2025-08-20 | 8-K | View |
| 2025-08-15 | 424B3 | View |
| 2025-08-14 | 4 | View |
| 2025-08-14 | 4 | View |
| 2025-08-14 | 4 | View |
| 2025-08-14 | 4 | View |